@inproceedings{inproceedings, title = {{Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis}}, url = {{}}, year = {{2021}}, month = {{1}}, author = {{Cork MJ and Thaci D and Eichenfield L and Arkwright PD and Chen Z and O'Malley JT and Bansal A}}, volume = {{185}}, journal = {{BRITISH JOURNAL OF DERMATOLOGY}}, issue = {{3}}, pages = {{E115-E116}}, note = {{Accessed on 2025/05/24}}}